Nature子刊：莫然/顾臻合作开发免疫刺激性脂质凝胶植入物，增强癌症免疫治疗
Merged summary
TL;DR — 研究团队开发了一种免疫刺激性脂质凝胶植入物，通过差异化持续释放全反式维甲酸和阿霉素，增强对耐药、癌症干细胞样肿瘤的免疫治疗效果。小鼠实验显示，该植入物可协同免疫检查点抑制剂，并抑制转移及术后复发。
- 该植入物采用溶致液晶凝胶，同时递送全反式维甲酸和阿霉素。
- 两种药物具有不同的持续释放曲线，可促进耐药癌症干细胞样细胞发生免疫原性死亡。
- 局部植入能够激活抗肿瘤免疫，并提高免疫检查点抑制剂的疗效。
- 在小鼠模型中，该策略有助于控制肿瘤转移和术后复发。
- 研究发表于 Nature Nanotechnology。
注： 第二则来源摘要介绍的是细胞外囊泡代谢检测平台 ACTIVE，与标题所述脂质凝胶植入物并非同一项工作，因此未合并其技术内容。
Sources (2)
Nature子刊：莫然/顾臻合作开发免疫刺激性脂质凝胶植入物，增强癌症免疫治疗
TL;DR - Researchers developed an immunostimulatory lipogel implant that locally delivers two cancer drugs with distinct release profiles. In mouse models, it enhanced checkpoint immunotherapy against stem-like tumors and helped suppress metastasis and postoperative recurrence.
- The lyotropic liquid-crystal gel co-delivers all-trans retinoic acid and doxorubicin.
- Differential sustained release promotes immunogenic cell death in drug-resistant, cancer stem-like cells.
- Local implantation stimulates antitumor immunity and improves synergy with immune checkpoint inhibitors.
- The work was published in Nature Nanotechnology.
Nature子刊：细胞外囊泡的催化谱分析，全面揭示癌症代谢改变
TL;DR - A Nature Nanotechnology study introduces ACTIVE, a programmable nanotechnology platform that profiles extracellular-vesicle metabolites directly from patient biofluids, enabling minimally invasive mapping of cancer metabolism and prognosis stratification.
- ACTIVE uses engineered catalytic bio–abiotic nanohybrids to quantify low-abundance EV-associated metabolites.
- Its catalytic efficiency exceeded wild-type catalysts by more than 30-fold, while detection limits in native biofluids improved over 1,000-fold.
- The platform captured broad metabolite profiles and metabolic-conversion dynamics across EV subpopulations.
- Using 5 μL of native ascites, ACTIVE identified tumor-microenvironment metabolic reprogramming patterns associated with patient prognosis.